CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2024; 8: (4) ; 12-14 ; DOI: 10.12208/j.ijcr.20240135.

Comparative analysis of the therapeutic effects of micro transplantation combined with chemotherapy and simple chemotherapy in the treatment of high-risk myelodysplastic syndrome
微移植联合化疗与单纯化疗治疗较高危骨髓增生异常综合征的疗效比较分析

作者: 苏敏利 *

呼和浩特市第一医院 内蒙古呼和浩特

*通讯作者: 苏敏利,单位:呼和浩特市第一医院 内蒙古呼和浩特;

发布时间: 2024-04-27 总浏览量: 188

摘要

目的 观察较高危骨髓增生异常综合征患者采取单一化疗与微移植联合化疗方案的疗效差异。方法 对照组选自本院2019年1月至2022年4月收治较高危骨髓增生异常综合征患者16例,均采取单一化疗。观察组选自本市患者就诊省外其他医院经采取微移植、化疗联合方案治疗后定期在我科门诊随访的患者8例。评价两组临床疗效、造血恢复时间、生存情况。结果 观察组较对照组,前者总有效率提高幅度更为明显(P<0.05)。对比中性粒细胞恢复时间、血小板恢复时间,观察组较对照组有更为明显减少(P<0.05)。观察组与对照组比较,其1年、2年的无进展生存期、总生存期均高于对照组(P<0.05)。结论 较高危骨髓增生异常综合征患者采取微移植、化疗联合方案可明显提升临床疗效,提高生存率。

关键词: 较高危骨髓增生异常综合征;化疗;微移植

Abstract

Objective To observe the difference between single chemotherapy and microtransplantation combined chemotherapy in high-risk patients with myelodysplastic syndrome.
Methods Part of the study cases were selected from 16 patients with high-risk myelodysplastic syndrome admitted to our hospital from January 2019 to April 2022 to form the control group, all of whom received single chemotherapy. Observation group 8 patients were selected from other hospitals outside the province who were regularly followed up in our department after microtransplantation and chemotherapy combined treatment. The clinical efficacy, hematopoietic recovery time and survival of the two groups were evaluated.
Results Compared with the control group, the total effective rate of the observation group increased more significantly (P < 0.05). Compared with the control group, the recovery time of neutrophil and platelet was significantly reduced in the observation group (P < 0.05). Compared with the control group, the 1-year and 2-year progression-free survival and overall survival of the observation group were higher than those of the control group (P < 0.05).
Conclusion   The combination of microtransplantation and chemotherapy can significantly improve the clinical efficacy and survival rate of patients with high-risk myelodysplastic syndrome.

Key words: High risk myelodysplastic syndrome; Chemotherapy; Micro-transplantation

参考文献 References

[1] 唐元艳,熊涛,梁艳,等. 微移植联合化疗与单纯化疗治疗较高危骨髓增生异常综合征的疗效比较[J]. 现代肿瘤医学,2020,28(3):447-450.

[2] 王博,肖韵悦,沈英英,等. 抗白延年汤1号方联合预激化疗方案治疗中高危骨髓增生异常综合征临床研究[J]. 新中医,2020,52(10):60-64.

[3] 宋立孝,陶善东,丁亦含,等. 地西他滨为主化疗方案联合微移植巩固治疗伴TP53突变骨髓增生异常综合征老年患者一例并文献复习[J]. 白血病·淋巴瘤,2021,30(6): 371-373.

[4] 张然,陆铉,严晗,等. 降低高危骨髓增生异常综合征异基因造血干细胞移植后复发的策略研究[J]. 中华器官移植杂志,2021,42(4):197-202.

[5] 黄龄乐,颜新宇,王欣,等. 71例中高危骨髓增生异常综合征患者化学药物治疗方案选择与生存分析[J]. 中国药业,2023,32(8):43-48.

[6] 蒋煜新,张灵,陈子兴,等. 影响造血干细胞移植的骨髓增生异常综合征患者生存期的因素分析[J]. 中国实验血液学杂志,2020,28(4):1283-1291.

[7] 张玉培,谢新生,石雅洁,等. 异基因造血干细胞移植治疗ASXL1基因突变的骨髓增生异常综合征患者的效果[J]. 实用医学杂志,2023,39(23):3087-3092.

[8] 吴佳霏,王珺,王依景,郑博月,王宇,江川艳,董丹丹,李慧.B细胞淋巴瘤2表达与B细胞淋巴瘤2抑制剂在骨髓增生异常综合征患者中疗效的相关性研究[J].中国全科医学,2024,27(17):2113-2118.

[9] 代喜平,王国征,林双,吴远彬,胡永珍,李达.补血方联合造血刺激治疗相对高危骨髓增生异常综合征患者的疗效观察[J].世界中西医结合杂志,2023,18(5):965-969, 974.

引用本文

苏敏利, 微移植联合化疗与单纯化疗治疗较高危骨髓增生异常综合征的疗效比较分析[J]. 国际临床研究杂志, 2024; 8: (4) : 12-14.